🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareFDA compounding enforcement update — June 2026 guidance document Page 15

FDA compounding enforcement update — June 2026 guidance document

RegAffairsDC Mon, Feb 26, 2024 at 4:00 PM 336 replies 53,782 viewsPage 15 of 20
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Mar 21, 2024 at 5:24 PM#71

Adding the clinical framing, because it changes how the question reads. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

Last edited: Mar 21, 2024 at 9:24 PM
30 5CryptoCarl, MariaRD, AussieAnna and 27 others
Reply Quote Save Share Report
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Mar 22, 2024 at 3:01 AM#72
anders_CPH said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Can confirm. Same sequence, different timescale.

29 4hannah_MT, Dr.SportsMedIN, amy_econ_NJ and 26 others
Reply Quote Save Share Report
tony_orlando
Member
234
1,123
Nov 2024
Orlando, FL
Mar 22, 2024 at 12:38 PM#73
anders_CPH said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Adding the part of the answer the thread has not reached. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Happy to go further on any of that.

28 3ZaraB_AL, JakeSmashed95, NauseaFreeNow and 25 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Mar 22, 2024 at 10:15 PM#74

One concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Happy to go further on any of that.

Last edited: Mar 22, 2024 at 11:15 PM
27 2PharmHunterJen, TomTeleRx, DoseLogDan and 24 others
Reply Quote Save Share Report
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
Mar 23, 2024 at 7:53 AM#75

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Mar 23, 2024 at 12:53 PM
26 1RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 23 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register